Jose F. Leis, MD, PhD, of the Mayo Clinic, and Sagar Lonial, MD, of Emory University, discuss a session on CLL treatment (excluding transplantation): ibrutinib resistance, transformation, and cellular therapy.
Marie Bleakley, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses data on using naive T-cell depletion of peripheral blood stem cells, which led to very low rates of chronic graft-vs-host-disease and high survival (Abstract 668).
Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the first-line setting (Abstract 471).
Brenda M. Sandmaier, MD, of Fred Hutchinson Cancer Research Center, and Sagar Lonial, MD, of Emory University, discuss study findings on sirolimus combined with mycophenolate mofetil and cyclosporine to improve prevention of acute graft-vs-host-disease after unrelated hematopoietic cell transplantation (Abstract 506).
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Nelli Bejanyan, MD, of the University of Minnesota, discuss findings from a study conducted by the Center for International Blood and Marrow Transplant Research on treatment for ALL patients, with an available donor, undergoing myeloablative allogeneic hematopoietic cell transplantation in first complete remission (Abstract 684).
Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (Abstract 470).
